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SUMMARY 
Objective: Prescribing, adherence, and adverse drug 
events to HAART in a large antiretroviral programme 
in Lagos was evaluated.  
Design A retrospective 5 year open cohort study 
Setting The AIDS Prevention Initiative in Nigeria 
(APIN) clinic at LUTH is one of the United States 
Presidential Emergency Plan for AIDS Relief (PEP-
FAR) funded centers for HIV relief program in Nigeria  
Participants The case files of 390 patients on HAART 
and attending the APIN clinic were reviewed sequel to 
random selection.  
Main outcome measures: Demographics of the pa-
tients and pattern of antiretroviral (ARV) combination 
drugs prescribed were extracted from their case files. 
The details of the adverse drug events (ADEs) were 
extracted from drug toxicity forms regularly filled for 
each patient. A Chi-square test with Yates correction 
was used to determine the association between adher-
ence and therapeutic outcome  
Results A total of 2944 prescriptions were assessed. 
Zidovudine + lamivudine + nevirapine (35.87%) and 
stavudine + lamivudine + nevirapine (35.63%) were 
the most frequently prescribed combinations. Over 
2000 ADEs were reported with cough (13.3%), fever 
(8.75%) and skin rashes (8.01%) being the most fre-
quently reported. Drug adherence was associated with 
good therapeutic outcome (χ2 = 115.60, p<0.0001).  
Conclusions: Zidovudine + lamivudine + nevirapine 
was the most frequently prescribed ARV combination. 
Cough was the most frequently reported ADE. Inter-
ventions aimed at rational prescribing of ARV drugs 
and improving adherence to antiretroviral drugs is es-
sential for good therapeutic outcome in the treatment of 
HIV infection. 
Keywords: Pharmacoepidemiology, antiretroviral 
drugs, drug adherence, adverse events 
 
INTRODUCTION 
Infection with Human Immunodeficiency Virus (HIV) 
and its progression to Acquired Immunodeficiency 
Syndrome (AIDS) have been a global crisis and a big 
challenge plaguing the healthy living of human today. 
It erodes both social and economic development as a 
result of its great influence on family stability, life ex-
pectancy and economic development.1 The burden is 
high globally as it remains the greatest health crisis 
facing the world today. There are approximately 34 
million people currently living with HIV and nearly 30 
million people have died of AIDS-related causes since 
the beginning of the epidemic.2,3 The highest propor-
tion of people living with HIV (97%) resides in low- 
and middle-income countries, particularly in sub-
Saharan Africa.4 
 
The use of highly active antiretroviral therapy 
(HAART) has resulted in a significant reduction in the 
morbidity and mortality related to AIDS. HAART is 
defined as the concurrent use of a combination of three 
or more ARV drugs to suppress HIV replication. It 
represents the current standard of care of antiretroviral 
therapy (ART) for HIV-infected patients.5 This strategy 
evolved from the recognition that treatment of chronic 
HIV infection with only one or two ARV drugs may 
result in rapid treatment failure and the development of 
resistance to the ARV drugs, which may compromise 
future therapeutic options.5,6 About a quarter of patients 
on ART discontinued the treatment within the first 
eight months due to treatment failure, adverse drug 
toxicity or non-compliance with the therapy.7,8  
 
 






There is also abundant evidence indicating that treat-
ment success is dependent on adherence to ARV 
drugs.9,10 However, adverse toxicity of the ARV drugs 
has been reported to also impart negatively on adher-
ence to treatment.9-11 
 
It is, therefore, necessary that clinicians have a clear 
understanding of the potential adverse effects of the 
ARV drugs. In addition, they should be able to readily 
recognise adverse effects in patients and manage them 
effectively. The risk of specific adverse effects varies 
from one ARV drug to another, from one drug class to 
another, and from one patient to another.12 The spec-
trum of adverse effects associated with ARVs may also 
vary between developed and developing countries.13 
 
The nucleoside reverse transcriptase inhibitors (NRTIs) 
are associated with lactic acidosis, lipodystrophy, and 
hyperlipidemia9,11, while the non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) are associated with 
neuropsychiatric symptoms, rash, liver toxicity, and 
lipid abnormalities.11 Protease inhibitors (PIs) are asso-
ciated with gastrointestinal intolerance and glucose and 
lipid abnormalities9. The entry inhibitor (maraviroc) 
and the integrase inhibitor (raltegravir) are new drugs 
used for treatment-naive and treatment-experienced 
patients. Maraviroc is associated with bronchitis, naso-
pharyngitis, and esophageal candidiasis, while ralte-
gravir is associated with increased risk of myopathy 
and rhabdomyolysis.14 
 
 There have been reports of adverse events to specific 
ARV drugs which include peripheral neuropathy and 
lipodystrophy associated with stavudine10, 15, anaemia 
associated with zidovudine16, 17, and nevirapine based 
hepatotoxicity and rash9, 18-20. The incidence of hepato-
toxicity has been reported as 8% and 16% for patients 
on efavirenz (EFV) and nevirapine (NVP), respective-
ly20, while the incidence of anaemia associated with 
zidovudine ranged from 3- 12% in developing coun-
tries.13 
 
As a means of improving adherence to ARV drugs, 
newer ones are available as fixed- dose combination21. 
Despite the decreased pill counts and frequency of dos-
ing per day for usual starting regimens, ART continue 
to have significant adverse effects that require monitor-
ing for drug interactions and long-term morbidity relat-
ed to cardiovascular, dermatological, bone, musculo-
skeletal and kidney disease.22 Most clinical trials have 
a relatively short follow-up duration and can underes-
timate longer term complications of therapy.  
 
A six years follow-up of patients in a Swiss Cohort 
study showed the presence of laboratory adverse events 
that was associated with higher rates of mortality, high-
lighting the importance of adverse events in overall 
patient management.23 
 
Several factors may predispose individuals to adverse 
effects of ARV drugs. Females appear to have a higher 
risk than male to develop Stevens-Johnson syndrome, 
rashes, and hepatotoxicity from NVP.24,25 Females are 
also at higher risk than males to develop lactic acidosis 
from NRTIs.26,27 Other risk factors include concomitant 
use of medications with overlapping and additive toxic-
ities; comorbid conditions that may increase the risk of 
or exacerbate adverse effects such as alcoholism28 or 
co-infection with viral hepatitis, which may increase 
risk of hepatotoxicity20; drug-drug interactions that 
may lead to an increase in drug toxicities; or genetic 
factors predisposing patients to abacavir (ABC) hyper-
sensitivity reaction.29 
 
Although the therapeutic goals of ART include achiev-
ing and maintaining viral suppression and improving 
immune function, an overall goal should be to select a 
regimen that is not only effective but also is safe. This 
requires consideration of not only the toxicity potential 
of the ARV drugs but also an individual patient’s un-
derlying conditions, concomitant medications, and pri-
or history of drug intolerances. 
 
Given the paucity of data on the use and reporting of 
the adverse effects of ARV drugs in HIV-infected 
adults in Nigeria, we aimed to determine the prescrib-
ing pattern of ARV drugs used at the AIDS Prevention 
Initiative in Nigeria (APIN) clinic, LUTH. In addition, 
we also determined the levels of adherence to the 




We retrospectively analysed the clinical records of 
HIV-infected adults who were receiving treatment at 
the AIDS Prevention Initiative in Nigeria (APIN) clinic 
at the Lagos University Teaching Hospital (LUTH) in 
Nigeria, between January 2005 and June 2009. The 
APIN clinic at LUTH is one of the United States’ Pres-
idential Emergency Plan for AIDS Relief-funded cen-
tres for the HIV relief program. The clinic is held every 
Monday through Friday, between 8 am and 4 pm.   
 
An average of 250 old and new patients (adults and 
children) is attended to daily at the APIN clinic. The 
ARV drugs are dispensed free of charge, on monthly 
basis, to about 8,000 registered HIV infected patients 
including men, pregnant and non-pregnant women and 










Only adult patients (male and female) were included in 
this study. Other inclusion criteria were patient older 
than 12 years, non-pregnant women, confirmed HIV-
infection with western blot test, patients with or with-
out AIDS presentation according to the criteria set out 
by the World Health Organization (WHO).30  
 
Patient must have been enrolled on ART only at the 
APIN clinic, LUTH and they must have used ARV 
drugs, at least once, after enrolment. Patients must also 
have completely documented demographic information 
and prescribed medications in the case files. Patients 
who died during the course of treatment, stopped or 
changed treatment were also included in the study.  
 
Children and pregnant women are special population 
group that were excluded. Patients who were trans-
ferred to other hospitals, or had multiple co-morbidities 
and concomitant prescription of drugs with potential 
adverse interactions (rifampicin, clarithromycin, flu-
conazole, and ketoconazole) with the recommended 
ARV drugs, were also excluded. The morbid condi-
tions included tuberculosis, cancer, diabetes and other 
medical conditions. We equally excluded the patients 
who were not willing to participate in the study.  
 
Sample Size determination 
Raosoft® sample size calculator was used to determine 
the sample size31. A sample size of 367 was calculated 
from the 8000 population of registered patients on 
ARV drugs using 5% error margin at 95% confidence 
interval, assuming 50% of the patients have all the 
measured outcomes documented in their case files. 
However, a sample size of 390 patients was used for 
ease of data analysis.  
 
Data abstraction 
Eligible cases were identified through the main register 
obtained from the medical record of the APIN clinic. 
Each patient was assigned an identification number and 
the case file randomly selected using a web-based ran-
dom sampling method. One of the researchers re-
viewed each case file, and—using a standard form pur-
posely designed for the study—extracted data on the 
demographics, concurrent infections at first presenta-
tion and follow-up, co-prescribed drugs, and the ART 
regimen prescribed. Other important information ex-
tracted included the results of routine immunological, 
virological and haematological investigations at base-
line and follow-up. We also extracted information on 
the relevant clinical signs and symptoms recorded be-
fore and after the commencement of ART. Document-
ed adverse drug events were also extracted from the 
case files.   
 
Data initially extracted were corroborated by two other 
researchers (a clinical pharmacist and a clinical phar-
macologist with medical background). There was 85% 
agreement between the three reviewers using Kappa 
statistics. The opinion of a fourth reviewer (a clinical 
pharmacologist with pharmacy background), however, 
superseded in those areas of disagreement.  
 
Prescribed ART regimen 
The national guidelines for HIV treatment in Nigeria 
recommended first-line ARV drugs for adults as zidov-
udine (AZT) or tenofovir (TDF) with lamivudine 
(3TC) or emtricitabine (FTC) and nevirapine (NVP) or 
efavirenz (EFV) 32. Second-line ARV drugs were rec-
ommended when there was therapeutic failure or se-
vere adverse effects to the first line combination. The 
regimens included AZT-3TC or FTC and TDF or dida-
nosine (ddI) or abacavir (ABC) plus lopinavir/ritonavir 
(LPV/r). The prescribed ARV drugs that were outside 
of those recommended by the WHO or national guide-
lines were considered as others. 
 
Adherence and treatment failure 
Adherence was defined according to the method of 
Arnsten et al.33 (the percentage of doses taken as pre-
scribed). It was measured by expressing the number of 
doses taken as a percentage of the total number of dos-
es prescribed. For example if 20 doses were prescribed 
and 19 doses were taken by a patient, the adherence is 
95%. This translates to missing one dose in ten days on 
a twice daily regimen. The number of doses taken was 
determined, during each month’s drug pickup through 
three days preceding clinic visit recall. Adherence was 
considered good when it was 95% and above or poor 
when it was below 95%.  
 
The adherence levels were correlated with therapeutic 
outcome through laboratory measurement of CD4+ cell 
count and viral load. Therapeutic outcome was good 
when the CD4+ cell count increased by at least 50 to 
100 cells/dL and the viral load was reduced to unde-
tectable level within 3 to 6 months of commencing 
ARV therapy34. Virological failure occurred when the 
viral load failed to reduce to undetectable level within 
3 to 6 months of commencement of HAART and when 
the CD4+ cell count did not increase by at least 50 cells 




The major outcomes measured were the types and fre-
quency of ART regimens prescribed, adherence to 
treatments, and the types and frequency of adverse 
events to the ARV drugs experienced by the patients. 
Data were analyzed using simple descriptive statistics. 
 
 






A Chi-square test with Yates correction was used to 
determine an association between adherence and thera-
peutic outcome at a 5% level of significance.                                                                                                                                                                                                                                                                                                                           
 
Ethical considerations 
The research protocol was reviewed and approved by 




The records of 390 eligible patients were reviewed in 
this study. The median age of the patients was 32 
(range 13-67) years, while the mean age was 35years 
(sd 9.67). The socio-demographics of the patients are 
as presented in Table 1.  
 
Prescribed ART regimes 
A total of 2944 prescriptions were reviewed and 23 
different ARV drug combinations were prescribed.  
The patterns of ART regimens prescribed at the clinic 
are presented in Table 2. The most frequently pre-
scribed regimen was AZT-3TC-NVP, followed by 
D4T-3TC-NVP 






Male 144 37.00 
Female 246 63.00 
Educational status 
None 23 6.00 
Primary 86 22.00 
Secondary 152 39.00 
Post-secondary 129 33.00 
Marital status 
Married 246.0 63.00 
Single 92.0 24.00 
Widowed 21.0 5.00 
Divorced 15.0 4.00 
Separated 8.0 2.10 
Undocumented 8.0 2.00 
 
 
Table 2 Different Antiretroviral Drug Combinations and their Frequency of Prescription 




Total Number of each 
HAART prescriptions  
Percentage of each  
HAART Combination 
1 AZT / 3TC / NVP 145 1056    35.87  
2 D4T / 3TC / NVP 94 1049    35.63  
3 AZT / 3TC / EFV 32 223      7.57  
4 AZT / 3TC / NVP / LPV / r 16 135      4.59  
5 FTC/ TDF / NVP 2 99      3.36  
6 FTC / TDF / EFV 22 76      2.58  
7 DDI / 3TC / NVP 9 63      2.14  
8 FTC / TDF / AZT / LPV / r 7 49      1.66  
9 DDI / 3TC / EFV 5 36      1.22  
10 D4T / 3TC / EFV 7 34      1.15  
11 AZT / 3TC 11 29      0.99  
12 AZT/ 3TC / LPV / r 2 21      0.71  
13 FTC / TDF / SQV / r 4 20      0.68  
14 FTC/ TDF / LPV / r 1 7      0.24  
15 D4T / 3TC / IDV / r 1 7      0.24  
6 IDV / AZT /  3TC 1 1      0.03  
17 ABC / 3TC / SQV / r 1 6      0.20  
18 ABC / DDI / LPV / r 1 6      0.20  
19 TDF / 3TC  / SQV / r 1 6      0.20  
20 AZT / 3TC / SQV / r 2 14      0.48  
21 AZT / 3TC / NVF 1 3      0.10  
22 ENF / r / DRV / SQV / TDV  2      0.07  
23 ABC / 3TC / EFV 1 2      0.07  
 TOTAL  2944  100.00  
Abbreviations: Stavudine (D4T); Lamivudine (3TC); 
zidovudine (AZT); Efavirence (EFV); Tenofovir (TDF); 
Lopinavir/ritonavir (LPV/r); Saquinavir (SQV); Enfuvirtide (ENF); 
Abacavir (ABC); Darunavir (DRV); Didanosine (DDI); Indinavir 










Adherence and therapeutic outcome 
The majority of the patients (75%) with good adher-
ence had good therapeutic outcome and almost all 
(95%) of those who adhered poorly had therapeutic 
failure. Subjecting this to chi square analysis showed 
that drug adherence was associated with good thera-
peutic outcome (χ2 = 115.60, p<0.0001). Table 3 shows 
the association between adherence and therapeutic out-
come. 
 
 Table 3 Relationship between Adherence and Thera-
peutic outcome 
 
Adverse events associated with ARV drugs 
The adverse events associated with the use of the vari-
ous ARV drugs are summarized in Table 4.  
Only complaints or ailments that developed or were 
observed in each of the patients after the commence-
ment of therapy of a particular combination of an-
tiretroviral drugs were included. A total of 90 different 
adverse events were recorded ranging from minor 
symptoms such as rash and catarrh to serious ones such 
as hepatomegaly and death.  
 
The latter occurred in three patients one of whom took 
a combination of stavudine-lamivudine-nevirapine 
while the other two took a combination of zidovudine-
lamivudine-nevirapine. Table 4 showed the frequently 
reported adverse events to the ARV drugs with cough 
(13.3%), fever (8.75%), and skin rashes (8.01%) being 
the most frequently reported adverse events.  
 
Very few reports were made on several other adverse 
events including known and common adverse events to 
ARV drugs such as peripheral neuropathy (1.78%), 
nausea and vomiting (2.57%), anaemia and lipoatrophy 
(0.4%).  
 
Table 4 Adverse Drug Events of   Antiretroviral Drug Combinations at LUTH PEPFAR Clinic. 
 Frequency of reports from different ARV combinations 




















#OTHERS TOTAL % 
Gastro-intestinal system disorders 
(0600) 108 57 3 - - - 11 179 8.85% 
Abdominal pain 12 17 - - - - 4 33 1.63% 
Nausea and vomiting 35 7 3 - - - 7 52 2.57% 
Diarrhoea 61 33 - - - - - 94 4.65% 
Respiratory system disor-
ders(1100) 107 88 39 34 8 27 65 368 18.20% 
Catarrh / runny nose 30 8 - 8 - - 11 57 2.82% 
Nasal congestion 8 8 13 - - - 13 42 2.08% 
Cough 69 72 26 26 8 27 41 269 13.30% 
Central and peripheral nervous 
system disorders(041) 119 120 78 44 - 20 154 535 25.66% 
Fatigue 26 52 19 7 - - 33 137 6.77% 
Fever 58 29 25 8 - 4 53 177 8.75% 
Headache - 7 14 14 - 4 29 68 3.36% 
Anorexia 15 8 4 - - 4 19 50 2.57% 
Malaise 20 20 13 13 - 6 13 85 4.21% 




















#OTHERS TOTAL % 
Muscular-skeletal system disor-








Total p- value 
Poor 3 (5%) 54 (95%)  57(14.6%)  
Good 261(78%)  72 (22%) 333(85.4%)  
Total  264 (68%) 126 (32%)  390 (100%) <0.0001 
 
 






 Frequency of reports from different ARV combinations 




















#OTHERS TOTAL % 
Joint pain 15 22 3 2 - - 2 44 2.17% 
Body aches 79 15 19 15 - 5 9 142 7.02% 
Chest pain 19 17 5 2 5 - 5 53 2.62% 
Cardiovascular disorders(1010 - 25 - - - - 9 34 1.68% 
Hypertension - 25 - - - - 9 34 1.68% 
Skin and appendages disorders 
(0100) 155 25 21 - 4 - 60 265 13.10% 
Itchy skin 61 4 11 - 4 - 23 103 5.09% 
Skin rashes 94 21 10 - - - 37 162 8.01% 
Special senses disorders(0433) 15 5 5 - - - 11 36 1.78% 
Pain and numbness in hands and 
feet 15 5 5 - - - 11 36 1.78% 
Body as a whole – general disor-
der(1810) 31 5 - - 4 3 12 59 1.34% 
Death 2 1 - - - - - 3 0.15% 
Weight loss 10 4 - - 4 3 3 24  1.19% 
SUBTOTAL 633 375 170 95 25 53 331 1682 82.42% 
OTHERS** 127 86 29 17 4 11 67 341 16.74% 
TOTAL 760 461 199 112 29 64 398 2023 100.00% 
NOTES 
*WHO-ART Classification system code    
**Others: Abdominal enlargement (0.89%), alopecia (0.10%), amen-
orrhoea (0.54%), amnesia (0.05%), anaemia (0.15%), anal lesion 
(0.30%), anxiety (0.05%), aphakia (0.05%), bitter taste (0.59%), 
blurred vision (0.15%), boil (0.69%), breast reduction (0.05%), 
breast enlargement (0.10%), cheilitis (0.05%), chills (0.05%),  con-
stipation (0.15%), cracked lips (0.15%), crepitation (0.10%), de-
creased libido (0.15%), dizziness (0.44%), dyspepsia (0.10%), dysp-
nea (0.05%), ear ache (0.30%), eye pain (0.05%), eye redness 
(0.25%), eye itching (0.05%), genital wart (0.02%), hemiparesis 
(0.40%), heartburn (0.25%), insomnia (0.89%), lipodystrophy 
(0.15%), lymphadenopathy (0.84%), malaise (4.21%), mouth ulcer 
(0.30%), myalgia ( 0.05%), nephropathy (0.05%), nocturia (0.30%), 
obesity (0.35%), oral thrush (0.40%),  palpitation (0.02%), paraesthe-
sia (0.20%), pedal oedema (0.74%), polyuria (0.10%), rigors 
(0.59%), scarring of the cornea (0.05%), seizures (0.10%), shortness 
of breadth (0.44%), skin discoloration (0.05%), sore throat (0.50%), 
sore gum (0.35%), splenomegally (0.15%), tachycardia (0.05%), 
tachypnea (0.05%), toothache (0.20%), toxoplasmosis (0.10%), 
urinary frequency (0.40%), painful urination (0.40%) 
Vaginal discharge (0.04%), vagina itching (().74%), wrist swelling 
(0.05%) 
 
#Others: (7) DDI / 3TC / NVP,  (8) FTC / TDF / AZT / LPV / r  (9) 
DDI / 3TC / EFV,  (10) D4T / 3TC / EFV, (11) AZT/3TC, (12) 
AZT/3TC/LPV/r, (13) FTC/TDF/SQV/r,  (14) FTC/TDF/LPV/r, (15) 
D4T/3TC/IDV/r, (16) IDV/AZT/3TC, (17) ABC/3TC/SQV/r,  (18) 
ABC/DDI/LPV/r, (19) TDF/3TC/SQV/r, (20) AZT/3TC/SQV/r,  (21) 
AZT/3TC/NVF, (22) ENF/r/DRV/SQV/TDV and (23) 
ABC/3TC/EFV.               
  
 
Stavudine (D4T); Lamivudine (3TC); zidovudine (AZT); Efavirence 
(EFV); Tenofovir (TDF); Lopinavir/ritonavir (LPV/r)  
Saquinavir (SQV); Enfuvirtide (ENF); Abacavir (ABC); Darunavir 
(DRV);  Didanosine (DDI); Indinavir (IDV); Nelfinavir (NVF); 
Emtricitabine (FTC) Tenofovir (TDF); Lopinavir/ritonavir (LPV/r)  
 
DISCUSSION 
This study highlighted the major ARV drug combina-
tions prescribed at APIN Clinic, LUTH, in Nigeria and 
the adverse events associated with their use. These 
adverse events are well characterized and known to be 
associated with the combinations given.  The most fre-
quently prescribed combinations were AZT-3TC-NVP 
and D4T-3TC-NVP. These combinations and others 
prescribed are consistent with the guidelines of the 
WHO.30                                                                                                                                                                                                                                                   
 
The combinations are also in keeping with the recom-
mendations of the National guidelines for the use of 
ARV drugs in Nigeria.32 However the use of 23 differ-
ent ARV drug combinations in a single clinic did not 
reflect rational prescribing and was in contrast to the 
National treatment guidelines.32  
 
A closer look at these combinations revealed that less 
than 10% of them were due to treatment switches re-
sulting from treatment failure or drug related toxicities.  
 
 






This irrational prescribing would suggest a need for 
training and re-training of the doctors on rational 
pharmacotherapeutics of ARV drugs. 
 
The combination of AZT-3TC-EFV regimen, though 
recommended by the national guidelines, was less fre-
quently prescribed probably because of intolerance to 
EFV and its contraindication in pregnancy.35  
 
Majority of the patients were females, in their repro-
ductive ages, and are likely to get pregnant during their 
course of treatment. This may be the reason why an 
EFV-based ART was avoided in the patients.  
 
The preponderance of female patients (in their repro-
ductive ages) afflicted with HIV in this study is in 
agreement with the United Nations report that over half 
of the 33.3 million people estimated to be living with 
HIV and AIDS at the end of year 2009 were women.36 
Also, in Nigeria, HIV gender statistics in 2009 revealed 
that for age above 15 years, the prevalence was higher 
in women (52%) than in men (37%) and children 
(11%).37 Given that most often, the patients were lit-
erate, it will be appropriate to incorporate sex educa-
tion and enlightenment campaign against HIV, directed 
more towards the female gender by the Federal Minis-
try of Health, into HIV/AIDS preventive measures in 
Nigeria.  
 
Medication adherence is a sine qua non for good thera-
peutic outcome in the management of HIV/AIDS 
infection with antiretroviral drugs. According to the 
National treatment guideline, for a good therapeutic 
outcome, viral load should be reduced to undetectable 
levels and CD4+ cell counts should increase by a min-
imum of 100 cells/mm3 in a year.32 This should pro-
duce an accelerated response after three months of 
commencement of ART. Any result outside these val-
ues will amount to therapeutic failure which could 
manifest as immunological failure, virological failure 
or both.38 Virological failure occurs when the viral load 
is still detectable after 3 to 6 months of antiretroviral 
therapy while immunological failure is said to occur if 
the CD4+ cell counts fail to increase by, at least, 50 to 
100 cells/mm3 after 6 months to one year of antiretrovi-
ral therapy.38 
 
Our findings revealed a statistically significant associa-
tion between drug adherence and good therapeutic out-
come. For a quarter of the patients who were assessed 
to have adhered adequately and still had therapeutic 
failure, drug resistance could be responsible for this.  
 
There is, therefore, a need to undertake resistance stud-
ies in these patients since such a high level of re-
sistance in patients on ART should ring alarm bells 
globally. A similar result was  obtained in a study per-
formed  in Brazil in which some patients had 
therapeutic failure despite adequate adherence to ART 
regimen.38  
 
As a result, the choice of subsequent therapies proved 
to be difficult, since such failure generally resulted in 
the emergence of resistant mutations that could even 
cause cross-resistance between several ARV drugs of 
the same class. In this scenario, several studies have 
assessed the benefit of genotyping tests as a tool for 
assisting in the therapeutic rescue of patients with 
treatment failure.39 These studies have shown that, 
among patients with treatment failure, the use of geno-
typing tests led to a greater effectiveness regarding 
medication change, in comparison with the empirical 
choices that were habitually made.39  
 
The fact that patients may not truly disclose the number 
of doses of ARV drugs they have missed may also ac-
count for the therapeutic failure in this study since ad-
herence was assessed through recall.  As for those who 
adhered poorly, the complexity of  ART regimens, 
whether due to pill number, dosing frequency, meal 
restrictions or other issues along with adverse drug 
events  such as lip dystrophy, dyslipidemia, insulin 
resistance and a host of others may create intentional 
non-adherence and may have contributed to this prob-
lem.39  
 
Cough (13.3%) was the most frequently reported ad-
verse event associated with the use of ARV drugs. 
Except for  maraviroc, an HIV entry inhibitor, cough 
has not been reported  as a common adverse event  of 
ARV drugs 40 and in this study none of the patients was 
on maraviroc because it was not among the 23 different 
regimens prescribed.  The cough was unlikely due to 
tuberculosis as patients with this comorbidity were 
excluded. Cough could also be a symptom of advanced 
HIV infection rather than being an adverse event of 
ARV drugs. An evidence supporting this is found in a 
study carried out in India in which cough (72.1%)  was  
the second most common presenting symptom after 
weight loss (74.4%) in  drug- naive AIDS patients.41  
 
Because cough is not a well-documented adverse event 
to the prescribed ARV drugs in this study, it is difficult 
to identify the specific ARV drug responsible for this 
in a retrospective study. This will be the basis for a 
prospective study where causality between each ART 
regimen and cough can be adequately assessed. The 
prevalence of fever and rashes were considerable in 
this study. This could be due to the fact NVP-based 
ART regimen was the most frequently prescribed.  
 
 






Rash is a common adverse event associated with NVP 
and other NNRTIs.40  
 
A few medications can cause fever but it is considered 
an adverse effect of ARV drug if the fever was accom-
panied by a rash.  Fever and rash are symptoms of hy-
persensitivity reactions to some ARV drugs especially 
DRV and ABC.42 Only very few of the well-known and 
common adverse effects of ARV drugs such as lip dys-
trophy, peripheral neuropathy, nausea and vomiting 
were reported in this study. Patients with poor adher-
ence are more likely to report adverse drug events since 
these could contribute to their poor adherence status. 
 
Limitations  
One of the limitations of this study was lack of ade-
quate information on certain risk factors for adverse 
events.  For example, data was not obtained on co-
morbid conditions like tuberculosis as stated earlier. A 
prospective study involving recruitment of patients and 
long term follow up after initiation of ART would have 
provided more information and permitted more exten-
sive follow up. These would have allowed a better case 
causality assessment for any of the adverse events. 
Another limitation was incomplete laboratory data for 
many of the patients.    
 
Apart from viral load and CD4+ cell counts, other 
laboratory tests results like liver function test, creati-
nine clearance, lipid profiles and blood sugar level 
were not extracted for analysis because data were not 
available. Therefore, adverse events reported were 
mainly clinical. Furthermore some of the suspected 
ADEs reported were similar to the symptoms and signs 
 of HIV/AIDS which further reinforces the need to 
report the clinical stages at presentation and/or enrol-
ments. Patients on concomitant antimalarial medication  
(artemisinin-based combination therapy) were not ex-
cluded because of the burden of malaria in Nigeria. 
This group of drugs is known theoretically to interact 
adversely with ARV drugs43 and may have probably 
contributed to the observed adverse events. 
 
CONCLUSION 
A combination of AZT-3TC-NVP was the most fre-
quently prescribed ARV drugs in APIN clinic, LUTH. 
Many of the ART regimens prescribed were outside the 
WHO and national guidelines for HIV/AIDS treatment, 
suggesting an irrational prescription. Cough, fever and 
skin rashes were the most frequently reported adverse 
events by the patients. Intensive efforts are required to 
improve adherence, as this is essential for good thera-
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